Iron deficiency anemia is the most prevalent nutritional anemia in children across the globe, and pediatricians encounter it daily. The standard diagnostic playbook is well rehearsed: assess dietary iron intake, screen for hereditary conditions such as thalassemia or sickle cell disease, look for overt or occult blood loss, and consider impaired absorption. In this patient, the workup initially revealed a classic microcytic, hypochromic pattern on his complete blood count — red cells that were both smaller and paler than normal, with a reduced mean corpuscular hemoglobin — alongside biochemical markers confirming genuine iron depletion. His diet was adequate, and there was no family history to suggest an inherited anemia. That left the uncomfortable question of where his iron was going.

The answer, it turned out, was seeping away invisibly. Upper gastrointestinal endoscopy revealed ulcers in both the stomach and the duodenum, accompanied by H. pylori-associated gastritis. Chronic oozing from these lesions, too slow to ever produce visible blood in the stool, had been draining the boy’s iron reserves for months. The bacteria itself was confirmed with a carbon-13 urea breath test, a noninvasive diagnostic in which the patient ingests urea labeled with a stable isotope; H. pylori’s urease enzyme splits the urea, releasing labeled carbon dioxide that can be measured in exhaled breath. A positive result, combined with the endoscopic picture, gave the team a coherent etiological story: infection, ulceration, occult bleeding, and iron loss.

What makes the case striking is the complete absence of gastrointestinal symptoms. Peptic ulcer disease in adults typically announces itself with epigastric pain, often related to meals, and children are generally assumed to present similarly. This patient felt nothing in his abdomen. The authors of the report emphasize that this silence delayed consideration of gastrointestinal pathology altogether, a delay they argue is not merely anecdotal but representative of a broader blind spot in clinical practice, particularly in regions where H. pylori prevalence is high.

The biology behind this presentation is well characterized even when the clinical presentation is not. H. pylori colonizes the gastric mucosa, where it disrupts the protective mucus layer, triggers chronic inflammation, and can cause erosions and ulcers. At the same time, the organism competes directly with its host for iron: it expresses receptors that bind human lactoferrin and other iron-containing proteins, effectively pirating the micronutrient for its own metabolism. Chronic gastritis can also reduce gastric acid output and ascorbic acid levels, both of which are needed to convert dietary ferric iron into the ferrous form that the duodenum absorbs. The result is a double hit — ongoing blood loss plus impaired iron uptake — that can outpace any dietary compensation.

In children, the stakes of missing this diagnosis compound over time. Iron is essential not only for hemoglobin synthesis but for neurocognitive development, immune function, and physical growth. Prolonged deficiency during school-age years has been associated with fatigue, reduced exercise tolerance, and difficulties with concentration. An ulcer that goes untreated, meanwhile, carries risks of its own, including more significant hemorrhage, perforation, and scarring. Early identification of H. pylori as the driver therefore converts a potentially progressive, insidious illness into a readily reversible one: eradication therapy combining antibiotics with a proton pump inhibitor, followed by confirmation of cure, typically resolves both the infection and its hematological consequences.

The report’s authors, a team of pediatricians and gastroenterologists affiliated with hospitals in Jiashan, Shanghai, and Hangzhou, argue that refractory or unexplained iron deficiency anemia in children should prompt clinicians to look beyond the usual suspects. Even in the absence of abdominal pain, they recommend that H. pylori infection and peptic ulcer disease enter the differential diagnosis once dietary inadequacy, hereditary anemias, and other common causes of iron loss have been excluded. Noninvasive testing such as the urea breath test makes this a practical proposition even in primary care settings, though definitive characterization of mucosal disease still requires endoscopy.

The epidemiological backdrop gives the recommendation added urgency. H. pylori infects roughly half of the world’s population, with prevalence substantially higher in developing regions and in communities with crowded living conditions and limited sanitation. Most infected individuals never develop symptomatic disease, which is precisely what makes the infection so easy to overlook when it does cause harm. In pediatrics, where complaints are often vague and children may not articulate discomfort clearly, an asymptomatic presentation is less an anomaly than a hazard baked into the disease’s natural history.

There is also a lesson here about the limits of symptom-driven medicine. The traditional diagnostic heuristic — follow the patient’s complaints — works well for acute conditions but can fail for slow-burning processes that announce themselves only through laboratory abnormalities. A hemogram showing microcytic anemia is not a diagnosis; it is a question. In this case, answering that question required the clinical team to resist the reassuring absence of symptoms and pursue invasive and noninvasive testing until the source of iron loss was found. The boy’s pallor and fatigue were, in effect, the surface expression of a subterranean hemorrhage.

For clinicians, the takeaway is concrete: in a child with iron deficiency anemia that does not respond as expected to iron supplementation, or in which no dietary or hereditary explanation exists, testing for H. pylori deserves a place early in the workup rather than as a last resort. For parents, the message is subtler but no less important — persistent pallor and fatigue in a child warrant medical evaluation even when the child insists he feels fine. A bacterium as widespread and as quiet as H. pylori does not always announce its presence; sometimes the only evidence it leaves behind is in the blood count.

Subject of Research: Helicobacter pylori-related peptic ulcer disease presenting as isolated iron deficiency anemia in a child

Article Title: Helicobacter pylori-related peptic ulcer presenting as isolated iron deficiency anemia without typical gastrointestinal complaints in a child: a case report

Article References: Chen, X., Miao, S., Zou, S., Wang, Y., Chen, G., & Jiang, M. (2026). Helicobacter pylori-related peptic ulcer presenting as isolated iron deficiency anemia without typical gastrointestinal complaints in a child: a case report. BMC Infectious Diseases. https://doi.org/10.1186/s12879-026-14366-4

Image Credits: AI Generated

DOI: 10.1186/s12879-026-14366-4

Keywords: Helicobacter pylori, iron deficiency anemia, peptic ulcer, pediatrics, endoscopy, urea breath test, gastrointestinal bleeding, anemia, gastritis, case report, occult blood loss, BMC Infectious Diseases

The study, led by Bin Liu and Chungen Xing of the Second Affiliated Hospital of Soochow University together with colleagues at Chengdu Medical College-affiliated hospitals, assembled a cohort of 5,847 adult patients with gastrointestinal bleeding drawn from four publicly available critical care databases spanning 2008 to 2022: the MIMIC-IV database, the eICU Collaborative Research Database, the Northwestern Medicine ICU database, and the Salzburg Intensive Care database. All four repositories are hosted on the PhysioNet platform and contain de-identified electronic health record data released under institutional review board approval. To be included, patients needed at least twelve blood urea nitrogen observations during the first day of their ICU stay, a demanding requirement that ensured the researchers could map laboratory values onto an hourly grid and reconstruct genuine temporal patterns rather than isolated snapshots.

The cohort was seriously ill. ICU mortality ranged from 18.0 percent to 19.7 percent across the four databases, meaning roughly one in five patients died during their intensive care stay. Men made up between 56.5 and 58.7 percent of each cohort, with women comprising the remaining 41.3 to 43.5 percent. Gastrointestinal bleeding is one of the most common emergencies that brings patients into intensive care, and mortality prediction in this population has long relied on static scoring systems such as the Glasgow-Blatchford Score, the AIMS65 score, and the Rockall score, all of which incorporate admission laboratory values but cannot respond to how a patient evolves after arrival.

The analytical approach was deliberately layered. Generalized additive models, a flexible statistical framework capable of capturing nonlinear relationships without forcing them into rigid parametric shapes, were used to characterize how the concentration and duration of blood urea nitrogen abnormalities jointly related to outcomes. Adjusted logistic regression then evaluated fifteen distinct blood urea nitrogen ranges, allowing the team to ask not just whether high values were dangerous but exactly which thresholds mattered and for how long they needed to persist. Restricted cubic splines examined time-weighted blood urea nitrogen exposure, integrating both magnitude and persistence into a single measure. Finally, the researchers ran meta-analyses across the four databases, performed sensitivity analyses restricted to patients with denser measurement sets, and formally compared static models built on admission values alone against dynamic models that incorporated the full hourly trajectory.

The headline finding is strikingly simple. Patients whose blood urea nitrogen stayed below 30 milligrams per deciliter for more than twelve hours had substantially lower odds of ICU death, with odds ratios ranging from 0.40 to 0.62 across the databases. In other words, keeping this value in the low range through the critical first day was associated with roughly a forty to sixty percent reduction in the odds of mortality compared with patients whose values did not remain in that zone. At the opposite extreme, blood urea nitrogen of 50 milligrams per deciliter or higher sustained for more than eighteen hours markedly increased mortality odds, with odds ratios between 1.55 and 3.39. The dose-response logic is intuitive: the longer a patient remained in the dangerous range, the greater the accumulated risk.

The time-weighted analysis refined this picture further. Prolonged time spent within the 5 to 30 milligrams per deciliter band was associated with lower mortality odds, while greater cumulative exposure to the 40 to 70 milligrams per deciliter range increased risk. Crucially, the associations were nonlinear, meaning the relationship between urea nitrogen exposure and death was not a straight line but a curve with thresholds and inflection points. Equally important for the credibility of the findings, the meta-analysis detected no between-database heterogeneity, and the results remained broadly consistent when the analysis was repeated in subsets of patients with more densely sampled laboratory measurements, addressing the concern that sparse sampling might have distorted the hourly trajectories.

Blood urea nitrogen is a deceptively rich biomarker. The liver produces ammonia during protein metabolism, the urea cycle converts it into urea, and the kidneys excrete it, so blood levels rise with kidney dysfunction, with dehydration and reduced renal perfusion, and with the digestion of blood itself inside the gastrointestinal tract, since digested hemoglobin delivers a large protein load to the gut. In a bleeding patient, an elevated value therefore weaves together several ominous threads at once: hypovolemia, impaired organ perfusion, possible acute kidney injury, and ongoing or severe blood loss. Prior research has already linked elevated blood urea nitrogen to mortality in general ICU populations, in sepsis, in acute heart failure with cardiorenal syndrome, and in acute pancreatitis, and ratios combining urea nitrogen with albumin or creatinine have been proposed as prognostic tools across a range of conditions.

What this study adds is the temporal dimension. A single admission value tells you where a patient started; a trajectory tells you where they are heading. When the researchers compared static models built on admission blood urea nitrogen alone against dynamic models incorporating the hourly trajectory data, the improvement was measurable and statistically significant. The area under the receiver operating characteristic curve, a standard measure of discrimination, rose from 0.678 to 0.701 in the static models to between 0.718 and 0.748 in the dynamic models, with all differences reaching significance on DeLong testing at P values of 0.05 or below. The dynamic models also showed improved reclassification of patients into risk categories and lower Brier scores, indicating better-calibrated overall predictions rather than merely better ranking.

The clinical implications are immediate and practical. Blood urea nitrogen is already drawn repeatedly in virtually every ICU patient, so no new test, no new equipment, and no additional cost would be required to implement trajectory-based monitoring. What would change is interpretation: instead of treating each laboratory result as an isolated data point, early warning protocols could flag patients whose values climb into or persist within the higher ranges during the first day, prompting earlier endoscopic evaluation, more aggressive resuscitation, closer renal monitoring, or escalation of care. Conversely, patients whose values settle and remain below 30 milligrams per deciliter for more than half a day might be identified as lower risk, potentially guiding earlier de-escalation and better allocation of scarce intensive care resources.

The authors are careful about the limits of their design. This was a retrospective cohort study, so the associations describe risk stratification rather than proving that any particular intervention that lowers blood urea nitrogen would improve survival. The requirement for at least twelve measurements in the first twenty-four hours selects a monitored subset of patients, and although sensitivity analyses in denser-measurement subsets were reassuring, the findings will need prospective validation before they reshape guidelines. The datasets came from de-identified records under PhysioNet data use agreements, the study was reported following the TRIPOD statement for prediction research, and the authors declared no conflicts of interest. Even with those caveats, the message is compelling: one of the cheapest, oldest tests in medicine, read as a moving curve rather than a single number, may help clinicians see which bleeding patients are quietly sliding toward death while there is still time to intervene.

Subject of Research: Hourly blood urea nitrogen trajectories as predictors of ICU mortality in critically ill patients with gastrointestinal bleeding

Article Title: Hourly Blood Urea Nitrogen Trajectories and ICU Mortality Risk in Critically Ill Patients with Gastrointestinal Bleeding: A Multicenter Retrospective Cohort Study

Article References: Liu, B., Zheng, X., Xu, Z., Yan, H., Du, Y., Yong, Z., & Xing, C. (2026). Hourly Blood Urea Nitrogen Trajectories and ICU Mortality Risk in Critically Ill Patients with Gastrointestinal Bleeding: A Multicenter Retrospective Cohort Study. Advances in Therapy. https://doi.org/10.1007/s12325-026-03796-w

Image Credits: AI Generated

DOI: 10.1007/s12325-026-03796-w

Keywords: blood urea nitrogen, gastrointestinal bleeding, ICU mortality, risk stratification, dynamic trajectories, critical care, MIMIC-IV, eICU, retrospective cohort study, predictive modeling, acute kidney injury, biomarkers

Peptic ulcer bleeding, often abbreviated PUB, is one of the most feared complications in gastroenterology. It occurs when an open sore in the lining of the stomach or the first part of the small intestine erodes into a blood vessel, producing external digestive hemorrhage or a drop in hemoglobin greater than two grams per deciliter. Despite major advances in endoscopic therapy and acid suppression over the past two decades, patients who experience one such bleed remain at elevated risk of another. For those also taking antithrombotic medications—drugs such as antiplatelet agents and anticoagulants that are essential for preventing heart attacks and strokes—the calculus becomes even more delicate, because both the ulcer and the cardiovascular system compete for clinical attention.

The conventional wisdom, embedded in multiple international guidelines, holds that eradicating H. pylori, a spiral-shaped bacterium that colonizes the gastric mucosa and is a principal cause of peptic ulcer disease, is a cornerstone of preventing recurrent bleeding. Yet much of the evidence underpinning that recommendation predates the era of widespread, long-term proton pump inhibitor use, the powerful acid-suppressing drugs that have become near-universal prescriptions after a bleeding event. The Spanish team set out to test whether the bacterium still drives recurrence in a contemporary, real-world population in which acid suppression is the norm rather than the exception.

To answer the question, the investigators conducted a retrospective, multicenter cohort study of consecutive patients who suffered a first episode of peptic ulcer bleeding between 2008 and 2023 in real clinical settings across Spain. To be included, patients required endoscopically confirmed gastric or duodenal ulcers or erosions together with evidence of bleeding. Those with non-peptic causes of upper gastrointestinal hemorrhage, peptic ulcers without bleeding, bleeding from the small bowel or colon, missing clinical data, or death during the index hospitalization were excluded. Follow-up continued until the first recurrence of ulcer bleeding, death, loss to follow-up, or the end of the review period, yielding a mean observation time of 6.4 years with a standard deviation of 4.7 years—a remarkably long window for a study of this kind.

The cohort ultimately comprised 1,675 patients. At discharge after their first bleeding episode, 525 of them, or 31 percent, were prescribed antithrombotic therapy, while 1,021 patients, or 61 percent of the entire cohort, received long-term proton pump inhibitor prescriptions. Notably, among the antithrombotic users themselves, 429 patients, representing 82 percent, were given indefinite PPI therapy, underscoring just how thoroughly acid suppression has penetrated routine care for this group. After the initial bleed and any eradication treatment, 94 patients, or 5.6 percent, remained H. pylori-positive, 936 patients, or 56 percent, tested negative, and 645 patients, or 38 percent, were never tested for the bacterium—a sizable untested fraction that itself reflects themessiness of real-world medicine.

The headline finding for the whole cohort was striking. Overall, 7.2 percent of patients experienced a first recurrence of peptic ulcer bleeding during follow-up. But when the researchers stratified by H. pylori status, recurrence climbed to 22 percent among those who remained positive, fell to 7.7 percent among those who were negative, and dropped to just 4.2 percent among the untested. Using Cox regression analysis adjusted for age, sex, use of non-steroidal anti-inflammatory drugs, and long-term PPI prescription, the team calculated that patients who stayed H. pylori-positive had a 3.7-fold higher risk of recurrence compared with H. pylori-negative patients, with a 95 percent confidence interval of 2.3 to 6.1. When the comparison was restricted to patients who remained positive versus those who had been successfully eradicated, the risk was 4.7 times higher, with a confidence interval of 2.6 to 8.7. In other words, in the general population of bleeders, the bacterium remains a potent and measurable driver of recurrent hemorrhage.

The picture changed dramatically, however, when the researchers turned to the 525 patients on antithrombotic drugs. In this subgroup, the overall incidence of first recurrence was only 5.1 percent. Among H. pylori-positive antithrombotic users, recurrence reached 7.1 percent; among H. pylori-negative users, 8 percent; and among the untested, just 2 percent. Counterintuitively, the positive patients did not fare worse than the negative ones, and after statistical adjustment the team found no significant risk differences across H. pylori status groups. The wide confidence intervals that accompany such subgroup analyses temper any strong claims, but the signal is clear: within this heavily PPI-protected population, H. pylori status no longer predicted who would bleed again.

What might explain this apparent paradox? One plausible mechanism centers on gastric acidity itself. H. pylori promotes ulcer formation and recurrence partly through inflammation and disruption of the mucosal barrier, but acid secretion remains a critical cofactor in the cascade that turns a colonized stomach into a bleeding ulcer. Proton pump inhibitors suppress acid output profoundly and durably, and with 82 percent of antithrombotic users in this cohort taking them indefinitely, the pharmacological floor beneath the mucosa may be high enough that eradicating the bacterium adds little additional protection. In patients without such acid suppression, or in whom PPI therapy is intermittent, the bacterium retains its full pathogenic force—precisely the pattern the whole-cohort analysis revealed. The finding also echoes a broader shift in ulcer epidemiology: as H. pylori prevalence falls and non-steroidal anti-inflammatory drug and antithrombotic use rises, drug-induced mucosal injury has overtaken infection as the dominant cause of bleeding ulcers in many settings.

The authors are careful to frame their work as preliminary, and several limitations deserve attention. The retrospective design means the researchers depended on records and testing practices that varied across centers and years, and the 38 percent of patients never tested for H. pylori introduce the possibility of selection effects—clinicians may have been less likely to test patients they judged to be at low risk. The antithrombotic subgroup, though sizable at 525 patients, yielded relatively few recurrence events, which limits statistical power and widens uncertainty around the null finding. Confounding by indication is also possible, since patients receiving antithrombotics differ systematically from those who do not. The study’s ethics approval came from the ethics committee of Aragón under code EPA22/065, with the informed consent requirement waived owing to the observational design, and the statistical analysis was supported by the Group of Translational Research in Digestive Diseases of the Aragón Health Research Institute, the CIBERehd network, and the FORTALECE program of the Spanish Ministry of Science and Innovation.

Even with those caveats, the implications are hard to ignore. Millions of people worldwide take antithrombotic drugs for cardiovascular protection, and a meaningful share of them carry H. pylori or have uncertain infection status. If prolonged acid suppression largely neutralizes the bacterium’s contribution to recurrent bleeding in these patients, clinicians may be able to prioritize adherence to PPI therapy, careful antithrombotic dosing, and avoidance of non-steroidal anti-inflammatory drugs over exhaustive pursuit of eradication in every case. At the same time, the stark 3.7-fold elevation in recurrence risk among H. pylori-positive patients in the broader cohort is a vivid reminder that eradication remains essential for most survivors of ulcer bleeding. The study does not overturn the eradication paradigm; it carves out a well-defined exception and, in doing so, maps the boundary conditions of one of gastroenterology’s most durable beliefs. Larger prospective studies, ideally with systematic testing of all patients, will be needed to confirm where that boundary truly lies—but for now, the message from Spain is that in the modern, acid-suppressed, real-world clinic, the bacterium’s grip on bleeding risk may be loosening, at least for those whose hearts and vessels demand blood thinners.

Subject of Research: Helicobacter pylori status and recurrence of peptic ulcer bleeding in antithrombotic users

Article Title: No significant association between H. pylori status and peptic ulcer bleeding recurrence among antithrombotic users: a preliminary study in a real-world population with high PPI use

Article References: Martínez-Domínguez, S. J., Ceamanos-Ibarra, E., Gallego-Llera, B., Jiménez-Benedí, M., Bujanda, L., Jardón-Piérola, O., Izaguirre-Arostegi, A., Cuarán, C., Pascual, A., Almenara, L., & Lanas, Á. (2026). No significant association between H. pylori status and peptic ulcer bleeding recurrence among antithrombotic users: a preliminary study in a real-world population with high PPI use. BMC Medicine. https://doi.org/10.1186/s12916-026-05275-z

Image Credits: AI Generated

DOI: 10.1186/s12916-026-05275-z

Keywords: Helicobacter pylori, peptic ulcer bleeding, antithrombotics, proton pump inhibitors, gastrointestinal bleeding, ulcer recurrence, Cox regression, retrospective cohort study, NSAIDs, eradication, BMC Medicine, gastroenterology

The research team, drawn from Wenzhou People’s Hospital, the First Affiliated Hospital of Wenzhou Medical University, and Shanghai Tongji Hospital, set out to answer a deceptively simple question: do patients who experience gastrointestinal bleeding during first-line chemotherapy for gastrointestinal diffuse large B-cell lymphoma fare worse than those who do not? The challenge in answering such questions retrospectively is confounding. Patients who bleed may differ systematically from those who do not in age, disease stage, tumor biology, or overall fitness, and any of those differences could explain an apparent survival gap. To address this, the investigators turned to propensity score matching, a statistical technique borrowed from epidemiology that attempts to recreate the balance of a randomized trial using observational data.

The mechanics of the analysis are worth understanding, because they underpin the credibility of the findings. The team assembled a cohort of 79 patients with gastrointestinal diffuse large B-cell lymphoma treated with first-line chemotherapy. Within that group, nine patients developed gastrointestinal bleeding after treatment. Each bleeding patient was matched with two controls who did not bleed, producing a 1:2 matched design. The matching variables were chosen with care: gender, clinical stage, Hans classification, which is a widely used immunohistochemical scheme that stratifies diffuse large B-cell lymphoma into germinal center B-cell-like and activated B-cell-like subtypes, and Eastern Cooperative Oncology Group performance status, a standard measure of a patient’s functional fitness. By balancing these key determinants of outcome across the two groups, the researchers could isolate the effect of bleeding itself with far greater confidence than a crude comparison would allow.

The results were striking. Patients who suffered gastrointestinal bleeding after chemotherapy had significantly worse overall survival, with a P value of 0.006, and significantly worse progression-free survival, with a P value of 0.011. Survival curves, however, only tell part of the story. The researchers also examined how the lymphoma responded to treatment, and here the differences were dramatic. The complete response rate, which reflects the proportion of patients whose disease vanished entirely on imaging and clinical assessment, was just 11.11 percent in the bleeding group compared with 66.67 percent in the matched controls, a difference that reached statistical significance at P equals 0.013. The objective response rate, which combines complete and partial responses, was 66.67 percent among bleeders versus 100.00 percent among controls, with a P value of 0.029. In other words, patients who bled were far less likely to achieve a deep remission, and none of the matched controls escaped treatment without at least a partial response.

Perhaps the most forward-looking element of the study is its use of metabolic imaging to predict who will bleed. All of the patients in the cohort underwent baseline fluorine-18 fluorodeoxyglucose positron emission tomography combined with computed tomography, the workhorse of modern lymphoma staging. This technique exploits the fact that rapidly dividing cancer cells consume glucose voraciously; the radioactive glucose analog accumulates in tumor tissue, allowing clinicians to measure not just where disease sits but how metabolically active it is. The researchers focused on parameters specific to the gastrointestinal involvement: the gastrointestinal metabolic tumor volume, abbreviated GI-MTV, which quantifies the physical volume of metabolically active tumor in the gut, and the gastrointestinal total lesion glycolysis, or GI-TLG, which integrates tumor volume with glucose uptake intensity to estimate the total metabolic burden carried by the intestinal disease.

Both parameters proved predictive. Patients who went on to bleed had significantly higher baseline GI-MTV, with a P value of 0.002, and significantly higher GI-TLG, with a P value of 0.004. The biological interpretation is intuitive: bulky, metabolically ravenous tumors in the gastrointestinal wall inflict more local destruction, erode deeper into the mucosa and muscularis layers, and leave behind larger ulcerated craters when chemotherapy begins to kill the malignant cells. When that necrotic tissue sloughs away, exposed blood vessels in the gut wall can hemorrhage. The finding suggests that a routine pre-treatment PET/CT scan, which nearly every lymphoma patient already receives, contains actionable information about bleeding risk that has largely gone unexploited.

The survival analysis within the matched cohort added further texture. High Eastern Cooperative Oncology Group performance status, indicating a patient with significant functional impairment, was associated with poorer overall survival at P equals 0.032 and poorer progression-free survival at P equals 0.008. Whole-body metabolic tumor volume, or Wb-MTV, and total lesion glycolysis, or Wb-TLG, which capture the entire systemic tumor burden rather than just the gastrointestinal component, were each linked to worse overall survival, at P equals 0.012 and P equals 0.038 respectively. The international prognostic index, a composite clinical score incorporating age, stage, performance status, serum lactate dehydrogenase, and the number of extranodal disease sites, was associated with poorer progression-free survival at P equals 0.027. Together, these findings paint a coherent picture in which both the global burden of disease and the patient’s physiological reserve shape outcomes, with bleeding acting as a clinical marker of tumors that were already the most formidable.

One of the more reassuring aspects of the study concerns management. Gastrointestinal bleeding in this setting sounds catastrophic, and it can be, but the majority of events were handled without invasive intervention. Conservative medical therapy, which typically includes acid suppression, bowel rest, transfusion support, and careful monitoring, succeeded in 77.78 percent of the bleeding cases. The remaining 22.22 percent required endoscopic hemostasis, in which a flexible camera is passed into the digestive tract and bleeding vessels are cauterized, clipped, or injected with vasoconstrictive agents. None of the reported events in the matched analysis apparently demanded emergency surgery in the data presented, which is notable given that perforation and hemorrhage in the gut have historically been among the most feared complications of treating gastrointestinal lymphoma. The message for clinicians is twofold: vigilance is essential, but a calibrated, stepwise response beginning with medical management is often sufficient.

The broader significance of this work lies in how it reframes a familiar complication. Gastrointestinal bleeding after chemotherapy has long been treated as an unpredictable accident, a bolt from the blue that clinicians could only react to. This study suggests otherwise. The bleeding events clustered among patients with high metabolic tumor burden in the gut, and those patients also had the worst responses to therapy and the shortest survival. Bleeding, in this framing, is less a random event than a clinical manifestation of aggressive, bulky disease that chemotherapy is struggling to control. That reframing has practical consequences. Patients with high baseline GI-MTV and GI-TLG could be flagged for intensified surveillance during the first treatment cycles, with a low threshold for endoscopic evaluation if any sign of bleeding emerges. They might also be candidates for closer monitoring of hemoglobin and fecal occult blood, or for prophylactic gastroprotective strategies, though the study does not test such interventions directly.

Cautions remain. The study is retrospective and small, with only nine bleeding patients, and propensity score matching can only balance the confounders that are measured and included; unmeasured differences in tumor location, depth of invasion, or treatment details could still contribute. The researchers appropriately note that the work was approved by the ethics committee of the First Affiliated Hospital of Wenzhou Medical University and conducted under the principles of the Helsinki Declaration, with informed consent waived for the retrospective design but patient privacy protected. The research was supported by the Zhejiang Provincial Natural Science Foundation of China. Even with those limitations, the convergence of evidence is compelling: worse survival, worse response rates, and higher baseline metabolic burden all point in the same direction. For a disease that affects the digestive tract of thousands of patients worldwide each year, the ability to look at a pre-treatment PET/CT scan and identify who is most likely to bleed, and to understand that bleeding marks a population in need of heightened attention, represents a meaningful step toward safer and more personalized lymphoma care. The study is published open access, allowing clinicians everywhere to examine the data in full.

Subject of Research: Gastrointestinal bleeding as a prognostic factor after first-line chemotherapy in gastrointestinal diffuse large B-cell lymphoma

Article Title: Outcomes of gastrointestinal bleeding events after first-line chemotherapy in gastrointestinal-diffuse large B-cell lymphoma: a propensity-score matched analysis

Article References: Li, H., Shen, Y., Jia, S., Xu, F., Xue, B., & Ye, H. (2026). Outcomes of gastrointestinal bleeding events after first-line chemotherapy in gastrointestinal-diffuse large B-cell lymphoma: a propensity-score matched analysis. Annals of Hematology. https://doi.org/10.1007/s00277-026-07272-x

Image Credits: AI Generated

DOI: 10.1007/s00277-026-07272-x

Keywords: diffuse large B-cell lymphoma, gastrointestinal bleeding, chemotherapy, PET/CT, metabolic tumor volume, propensity score matching, prognosis, overall survival, progression-free survival, endoscopic hemostasis, Annals of Hematology, hematology

A portal cavernoma is defined as a network of veins, initially millimetric or even microscopic in size, that progressively dilates and through which hepatoportal blood continues to flow. It represents the body’s workaround for a problem: chronic occlusion of the extrahepatic portal system lasting more than three weeks. When the portal vein—the major vessel that channels nutrient-rich blood from the digestive organs to the liver—becomes irreversibly thrombosed, the surrounding tissue sprouts a tortuous meshwork of collateral channels to bypass the obstruction. First described in 1955 during the autopsy of a patient who died of mesenteric venous thrombosis, the condition has since become recognized as a significant cause of portal hypertension, but it remains sparsely documented in the African literature, particularly in sub-Saharan Africa, where only scattered case reports exist.

The patient’s initial presentation was deceptively ordinary. He had no particular medical history, yet he arrived with hematemesis—vomiting of blood—that had begun two days earlier, followed a day later by moderate diarrhea with blackish stools, a classic sign of digested blood passing through the gastrointestinal tract. There was no indication that he had consumed contaminated food or toxic substances. Clinical examination recorded a blood pressure of 100/60 mmHg, a heart rate elevated to 110 beats per minute, and a respiratory rate of 20 cycles per minute. His body mass index had fallen to 18 kg/m², signaling weight loss. Palpation revealed tenderness in the epigastric region, moderate ascites—fluid accumulating in the abdominal cavity—and an enlarged spleen consistent with Hackett stage II splenomegaly. Cardiac auscultation confirmed regular tachycardia at 110 beats per minute, a physiological compensation for volume loss.

Endoscopy performed shortly after admission revealed more than just the bulbar ulcer. The examination also identified grade IIa esophageal varices—dilated veins in the lining of the esophagus—without red signs, the endoscopic markers that predict imminent rupture. Additionally, the mucosa displayed a mosaic appearance, a hallmark of moderate portal hypertension. This combination should have raised a flag: peptic ulcers do not cause esophageal varices or mosaic mucosa, and both findings point toward elevated pressure in the portal venous system. Nevertheless, given the prominence of the ulcer and the positive H. pylori stool antigen test, the initial diagnosis of a bulbar ulcer was made, and eradication therapy was commenced. It was a reasonable start, but it addressed a contributor rather than the underlying engine of the disease.

The diagnostic turning point arrived two days later with an abdominal ultrasound. The study was consistent with heterogeneous portal vein thrombosis, accompanied by abundant ascites and, notably, a normal-sized, non-dysmorphic liver—an important observation, because cirrhosis is by far the most common cause of portal hypertension, and its absence demanded an alternative explanation. An abdominal computed tomography scan performed with portal vein injection then delivered the decisive findings. Contrast imaging revealed a heterogeneous filling defect in the portal trunk and its branches, with dilation of the vessels upstream of the obstruction, consistent with a thrombotic lesion of the portal trunk. The heterogeneous center of the lesion did not take up contrast, a pattern suggesting a portal cavernoma. The scan also demonstrated thrombosis of the splenic vein, a splenic nodule suggestive of an angioma, and an atrophic pancreas with a 9-millimeter dilation of the Wirsung duct, the main pancreatic duct.

Laboratory workup added nuance rather than contradiction. Transaminases were only slightly elevated, with AST at 44 IU/L and ALT at 48 IU/L, while the blood ionogram, complete blood count, and prothrombin level were all normal. Serology for HIV, hepatitis B, and hepatitis C came back negative, ruling out the viral infections that account for much of chronic liver disease worldwide. The etiological investigation, however, hit a practical wall: thrombophilia testing—including assays for protein C and S, antithrombin III, factor V Leiden, and the JAK2 mutation—could not be performed because these tests were simply unavailable in the clinical setting. This gap matters, because in adults the onset of portal vein thrombosis most often results from a combination of local and systemic prothrombotic factors, and guidelines call for systematic investigation of underlying thrombophilic disease.

With the imaging and clinical picture aligned, the team made their diagnosis: portal cavernoma revealed by gastrointestinal hemorrhage. The mechanism is elegant yet perilous. The portal obstruction creates a network of collateral veins of varying caliber through which hepatoportal blood is rerouted, but these fragile channels—and the varices they feed—operate under elevated pressure. In this patient, the hemorrhage was driven by rupture-prone esophageal varices, which occur in 90 to 95 percent of portal cavernoma cases, making variceal bleeding both the most common mode of presentation and the most feared complication. Other manifestations, including splenomegaly, abdominal pain, ascites, and transit disorders such as the patient’s diarrhea, are frequent but neither constant nor specific. The authors also point to portal hypertensive enteropathy and pancreatic atrophy as contributors to exocrine pancreatic insufficiency, which produces mucosal congestion, malabsorption, and diarrhea—a chain of physiological consequences that links seemingly unrelated symptoms back to the obstructed portal vein.

Treatment proceeded on several fronts simultaneously. The patient received 40 mg of injectable omeprazole every 12 hours to suppress acid and protect the ulcer, 40 mg of propranolol per day—a nonselective beta blocker that lowers portal pressure and provides primary or secondary prevention of variceal hemorrhage—and one sachet of Gaviscon every 8 hours. Endoscopic band ligation was performed to control the bleeding varices directly, and once hemorrhage was arrested, anticoagulation was initiated with 0.8 mL of enoxaparin every 12 hours, later transitioned to 4 mg of acenocoumarol daily with a target International Normalized Ratio of 2 to 3. Anticoagulation in portal cavernoma aims to prevent extension of thrombosis and, in some cases, to allow recanalization, though it must be balanced against the risk of rebleeding from varices.

The clinical evolution was favorable. Abdominal pain, ascites, and gastrointestinal bleeding all regressed, and the patient was discharged home after 10 days, following two stable INR readings of 2.3 and 2.5. Remarkably, no blood transfusion was required, as he remained hemodynamically stable with a hemoglobin level of 11 g/dL. He left the hospital on 40 mg of oral omeprazole twice daily and 4 mg of acenocoumarol, with anticoagulation planned for six months. At a three-month follow-up visit, he showed complete resolution of symptoms with a stable INR. Unfortunately, at the six-month mark the patient was lost to follow-up, and the team was unable to obtain follow-up imaging to assess whether the cavernoma had evolved, a sobering reminder of the practical challenges of longitudinal care in resource-limited settings.

The epidemiological context underscores just how unusual this case is. In the United States, the incidence of portal cavernoma is estimated at about 1 percent of the general population, based on large autopsy studies that documented portal vein thrombosis prevalence and lifetime risk across more than 23,000 consecutive examinations. In Africa, the true incidence is unknown but is thought to be below 1 percent according to the available literature. A Tunisian study in 2001 described just 19 observations over 25 years, while a Moroccan series reported 11 cases between 2003 and 2012. Most series show a male predominance, and the condition is overwhelmingly described in pediatric populations, where omphalitis—infection of the umbilical stump—remains a common cause of portal thrombosis in developing countries. In children, portal vein obstruction is also associated with growth retardation, attributed to reduced hepatoportal flow and resistance to growth hormone. Adult presentations in middle age, such as this one, are exceptionally rare in the published record.

The therapeutic hierarchy for portal cavernoma extends well beyond the medical management available to this patient. Beta blockers remain the cornerstone of hemorrhage prevention, but when endoscopic and pharmacological measures fail, ligation or sclerotherapy of varices is indicated, and in cases complicated by biliary symptoms—cavernomas can compress the bile ducts, producing a condition known as portal biliopathy—a porto-systemic shunt, with or without a porto-biliary shunt, may be required. Such surgical options demand infrastructure and expertise that are often unavailable in the settings where the disease is most likely to go undiagnosed. For the authors of this report, the case is a call to vigilance: when a patient presents with gastrointestinal hemorrhage and the endoscopy shows findings that exceed the usual scope of peptic ulcer disease, clinicians must look deeper into the portal vasculature. The ulcer, in this story, was real—but it was the supporting actor, not the star.